
Overview
Vasa Therapeutics develops therapies that target validated mechanisms in cardiovascular, neuromuscular and age-related disorders. Its pipeline includes four assets, including VS-041, a narrow-spectrum MMP-2 and MMP-9 inhibitor for heart failure with preserved ejection fraction, and long-acting apelin analogs for peripheral artery disease, neuromuscular diseases and sarcopenia.
Financials
Revenue history (in k)
From the notes
| Profit allocation | Loss to be covered | |
| Capital expenditure | $15,574 | |
| Contingent liabilities | Yes | |
| Management board pay | $57,132 | |
| Parent company | VASA THERAPEUTICS, INC. |
Filing timeliness
Financial statements were filed on time, on average 42 days early.
- 202501/07/2026
- 202401/07/2025
- 202303/06/2024
- 202230/06/2023
- 202120/05/2022
- 202028/06/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
- Research and experimental development in natural sciences and engineering (72.1)
Offer
- Cardiology medicines
- Neuromuscular drugs
- Anti-aging drugs
- Therapeutic candidates
Websites
- vasatherapeutics.comVasa TherapeuticsWebflow
Authorized Representatives
Manner of representation
In the case of a one-person management board, that member of the management board makes declarations of will on behalf of the company. In the case of a management board consisting of two or more persons, two members of the management board acting jointly or a member of the management board acting jointly with a commercial proxy are authorised to make declarations of will on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Vasa Therapeutics, Inc. | 189 | $2,552.67 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-07-20.
34 1090 2590 0000 0001 4486 8982
11 1090 2590 0000 0001 4684 4704
84 1090 2590 0000 0001 4486 8470
Debt
No entries in the National Debtors Register (KRZ).
Public aid
5 public aid cases recorded, with a total value of $5,532,661.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 14, 2025 | Aid for research and development projects: industrial research | $2.5M$2,456,182 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jan 14, 2025 | Aid for research and development projects: experimental development | $449.5K$449,461 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jan 14, 2025 | Aid for SMEs for innovation support | $15,068$15,068 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-01-01 | Development of an innovative matrix metalloproteinase (MMP) inhibitor as the first-in-class drug modifying the progression of MMVD and SAS in dogs. | $3.7M$3,728,386 | European Funds for a Modern Economy | |
| 2020-04-01 | Preclinical work and Phase I clinical trials of an innovative drug candidate for HFpEF heart failure | $2.6M$2,611,950 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Captor Therapeutics S.A. | $2,286,539.43 | captortherapeutics.pl | ||
| Molecure S.A. | $1,889,300.60 | molecure.com | ||
| Bioceltix S.A. | $616,315.97 | bioceltix.com | ||
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| Human Biome S.A. | $583,508.16 | human-biome.com | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Multiqure S.A. | $284,781.52 | purebiologics.com | ||
| WPD Pharmaceuticals S.A. | $87,561.70 | wpdpharmaceuticals.pl | ||
| Orphinic Scientific S.A. | $42,972.42 | orphinic.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-12-02 | Address change (Ul. Duńska 9/D009, 54-427, Wrocław → Ul. Duńska 9/2/23, 54-427, Wrocław) | |
| 2025-12-02 | Share capital increase (9,150.00 PLN → 9,450.00 PLN) | |
| 2024-10-23 | Share capital increase (8,350.00 PLN → 9,150.00 PLN) | |
| 2024-07-25 | Share capital increase (7,350.00 PLN → 8,350.00 PLN) | |
| 2024-02-22 | Share capital increase (6,350.00 PLN → 7,350.00 PLN) |
FAQ
Last updated: 2026-10-07